The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
National Cancer Institute. SEER cancer statistics review 1975-2013: myelodysplastic syndromes (MDS) chronic myeloproliferative disorders (CMD) and chronic myelomonocytic leukemia (CMML). 2016. Available at: http://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01.html. Accessed November 8 2016.
National Cancer Institute. SEER cancer statistics review 1975-2013: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). 2016. Available at: http://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01.html. Accessed November 8, 2016.
)| false
KaloutsiVKohlmeyerUMaschekH. Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. Am J Clin Pathol1994;101:123–129.
KaloutsiVKohlmeyerUMaschekH. Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. Am J Clin Pathol1994;101:123–129.
)| false
ValentPHornyHPBennettJM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res2007;31:727–736.
ValentPHornyHPBennettJM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res2007;31:727–736.
)| false
ArberDAOraziAHasserjianR. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood2016;127:2391–2405.
ArberDAOraziAHasserjianR. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood2016;127:2391–2405.
)| false
GreenbergPLTuechlerHSchanzJ. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood2016;128:2096–2097.
GreenbergPLTuechlerHSchanzJ. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood2016;128:2096–2097.
)| false
BrunningRBennettJFlandrinG. Myelodysplastic syndromes. In: JaffeEHarrisNSteinH eds. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:61–73.
BrunningRBennettJFlandrinG. Myelodysplastic syndromes. In: JaffeEHarrisNSteinH, eds. WHO Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:61–73.
)| false
HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:3835–3849.
HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:3835–3849.
)| false
BrunningROraziAGermingU. Myelodysplastic syndromes. In: SwerdlowSHCampoEHarrisNL eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008;87–104.
BrunningROraziAGermingU. Myelodysplastic syndromes. In: SwerdlowSHCampoEHarrisNL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.Lyon, France: IARC Press; 2008;87–104.
)| false
VardimanJWThieleJArberDA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937–951.
VardimanJWThieleJArberDA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937–951.
)| false
SchanzJTuchlerHSoleF. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol2012;30:820–829.
SchanzJTuchlerHSoleF. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol2012;30:820–829.
)| false
GermingULausekerMHildebrandtB. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia2012;26:1286–1292.
GermingULausekerMHildebrandtB. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia2012;26:1286–1292.
)| false
MalloMCerveraJSchanzJ. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia2011;25:110–120.
MalloMCerveraJSchanzJ. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia2011;25:110–120.
)| false
ArberDABrunningRDOraziA. Acute myeloid leukaemia with myelodysplastia-related changes. In: SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008:124–126.
ArberDABrunningRDOraziA. Acute myeloid leukaemia with myelodysplastia-related changes. In: SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.Lyon, France: IARC Press; 2008:124–126.
)| false
HasserjianRPCampigottoFKlepeisV. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with >/=30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol2014;89:e193–199.
HasserjianRPCampigottoFKlepeisV. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with >/=30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol2014;89:e193–199.
)| false
GermingUGattermannNStruppC. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res2000;24:983–992.
GermingUGattermannNStruppC. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res2000;24:983–992.
)| false
GermingUStruppCKuendgenA. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol2006;132:162–167.
GermingUStruppCKuendgenA. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol2006;132:162–167.
)| false
GermingUStruppCKuendgenA. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica2006;91:1596–1604.
GermingUStruppCKuendgenA. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica2006;91:1596–1604.
)| false
MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:7594–7603.
MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:7594–7603.
)| false
Muller-BerndorffHHaasPSKunzmannR. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol2006;85:502–513.
Muller-BerndorffHHaasPSKunzmannR. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol2006;85:502–513.
)| false
GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes[published correction appears in Blood 1998;2091:1100]. Blood1997;89:2079–2088.
GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes[published correction appears in Blood 1998;2091:1100]. Blood1997;89:2079–2088.
)| false
TaskesenEHavermansMvan LomK. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood2014;123:3327–3335.
TaskesenEHavermansMvan LomK. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood2014;123:3327–3335.
)| false
MeggendorferMBacherUAlpermannT. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia2013;27:1852–1860.
MeggendorferMBacherUAlpermannT. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia2013;27:1852–1860.
)| false
VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008:85–86.
VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.Lyon, France: IARC Press; 2008:85–86.
)| false
MalcovatiLPapaemmanuilEBowenDT. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood2011;118:6239–6246.
MalcovatiLPapaemmanuilEBowenDT. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood2011;118:6239–6246.
)| false
BejarRStevensonKECaugheyBA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol2012;30:3376–3382.
BejarRStevensonKECaugheyBA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol2012;30:3376–3382.
)| false
CazzolaMRossiMMalcovatiL. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood2013;121:260–269.
CazzolaMRossiMMalcovatiL. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood2013;121:260–269.
)| false
CargoCARowbothamNEvansPA. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood2015;126:2362–2365.
CargoCARowbothamNEvansPA. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood2015;126:2362–2365.
)| false
KwokBHallJMWitteJS. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood2015;126:2355–2361.
KwokBHallJMWitteJS. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood2015;126:2355–2361.
)| false
PapaemmanuilEGerstungMMalcovatiL. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood2013;122:3616–3627.
PapaemmanuilEGerstungMMalcovatiL. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood2013;122:3616–3627.
)| false
PatnaikMMItzyksonRLashoTL. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia2014;28:2206–2212.
PatnaikMMItzyksonRLashoTL. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia2014;28:2206–2212.
)| false
TholFKadeSSchlarmannC. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood2012;119:3578–3584.
TholFKadeSSchlarmannC. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood2012;119:3578–3584.
)| false
PatnaikMMLashoTLHodnefieldJM. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood2012;119:569–572.
PatnaikMMLashoTLHodnefieldJM. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood2012;119:569–572.
)| false
ItzyksonRKosmiderOCluzeauT. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia2011;25:1147–1152.
ItzyksonRKosmiderOCluzeauT. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia2011;25:1147–1152.
)| false
SebaaAAdesLBaran-MarzackF. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer2012;51:1086–1092.
SebaaAAdesLBaran-MarzackF. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer2012;51:1086–1092.
)| false
MalloMDel ReyMIbanezM. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol2013;162:74–86.
MalloMDel ReyMIbanezM. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol2013;162:74–86.
)| false
JaderstenMSaftLPellagattiA. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica2009;94:1762–1766.
JaderstenMSaftLPellagattiA. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica2009;94:1762–1766.
)| false
MohamedaliAMAlkhatabiHKulasekararajA. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood2013;122:567–570.
MohamedaliAMAlkhatabiHKulasekararajA. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood2013;122:567–570.
)| false
ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:3671–3674.
ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:3671–3674.
)| false
ChesonBDGreenbergPLBennettJM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood2006;108:419–425.
ChesonBDGreenbergPLBennettJM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood2006;108:419–425.
)| false
GreenbergPBaerMBennettJ. NCCN Practice Guidelines for Myelodysplastic Syndromes, Version1, 2001. The Complete Library of NCCN Guidelines [CD-ROM]. Rockledge, PA; 2001.
GreenbergPBaerMBennettJ. NCCN Practice Guidelines for Myelodysplastic Syndromes, Version1, 2001. The Complete Library of NCCN Guidelines [CD-ROM],. Rockledge, PA; 2001.
)| false
MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513–519.
MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513–519.
)| false
MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204–209.
MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204–209.
)| false
GiraldoPNomdedeuBLoscertalesJ. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer2006;107:2807–2816.
GiraldoPNomdedeuBLoscertalesJ. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer2006;107:2807–2816.
)| false
StasiRAbruzzeseELanzettaG. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol2005;16:1921–1927.
StasiRAbruzzeseELanzettaG. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol2005;16:1921–1927.
)| false
Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:68–75.
Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:68–75.
)| false
ParkSGrabarSKelaidiC. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood2008;111:574–582.
ParkSGrabarSKelaidiC. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood2008;111:574–582.
)| false
KelaidiCBeyne-RauzyOBraunT. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol2013;92:621–631.
KelaidiCBeyne-RauzyOBraunT. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol2013;92:621–631.
)| false
TehranchiRFadeelBSchmidt-MendeJ. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res2005;11:6291–6299.
TehranchiRFadeelBSchmidt-MendeJ. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res2005;11:6291–6299.
)| false
KelaidiCParkSBrechignacS. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res2008;32:1049–1053.
KelaidiCParkSBrechignacS. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res2008;32:1049–1053.
)| false
GreenbergPLSunZMillerKB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood2009;114:2393–2400.
GreenbergPLSunZMillerKB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood2009;114:2393–2400.
)| false
PhurroughSJacquesLCiccantiM. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=203&ver=12&NcaName=Erythropoiesis+Stimulating+Agents+&bc=BEAAAAAAIAAA. Accessed December 19 2017.
PhurroughSJacquesLCiccantiM. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=203&ver=12&NcaName=Erythropoiesis+Stimulating+Agents+&bc=BEAAAAAAIAAA. Accessed December 19, 2017.
)| false
FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223–232.
FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223–232.
)| false
KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:1794–1803.
KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:1794–1803.
)| false
LubbertMSuciuSBailaL. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol2011;29:1987–1996.
LubbertMSuciuSBailaL. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol2011;29:1987–1996.
)| false
SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Broup B. J Clin Oncol2002;20:2429–2440.
SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Broup B. J Clin Oncol2002;20:2429–2440.
)| false
SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:3895–3903.
SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:3895–3903.
)| false
SilvermanLRFenauxPMuftiGJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer2011;117:2697–2702.
SilvermanLRFenauxPMuftiGJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer2011;117:2697–2702.
)| false
LyonsRMCosgriffTMModiSS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol2009;27:1850–1856.
LyonsRMCosgriffTMModiSS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol2009;27:1850–1856.
)| false
MartinMGWalgrenRAProcknowE. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol2009;84:560–564.
MartinMGWalgrenRAProcknowE. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol2009;84:560–564.
)| false
LubbertMWijermansPKunzmannR. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol2001;114:349–357.
LubbertMWijermansPKunzmannR. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol2001;114:349–357.
)| false
WijermansPLubbertMVerhoefG. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol2000;18:956–962.
WijermansPLubbertMVerhoefG. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol2000;18:956–962.
)| false
van den BoschJLubbertMVerhoefGWijermansPW. The effects of 5-aza-2’-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res2004;28:785–790.
van den BoschJLubbertMVerhoefGWijermansPW. The effects of 5-aza-2’-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res2004;28:785–790.
)| false
SabaHILubbertMWijermansPW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2005;106:2515.
SabaHILubbertMWijermansPW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2005;106:2515.
)| false
KantarjianHMO'BrienSShanJ. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer2007;109:265–273.
KantarjianHMO'BrienSShanJ. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer2007;109:265–273.
)| false
KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:52–57.
KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:52–57.
)| false
DamajGDuhamelARobinM. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol2012;30:4533–4540.
DamajGDuhamelARobinM. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol2012;30:4533–4540.
)| false
FieldTPerkinsJHuangY. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant2010;45:255–260.
FieldTPerkinsJHuangY. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant2010;45:255–260.
)| false
GerdsATGooleyTAEsteyEH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant2012;18:1211–1218.
GerdsATGooleyTAEsteyEH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant2012;18:1211–1218.
)| false
LubbertMBertzHRuterB. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant2009;44:585–588.
LubbertMBertzHRuterB. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant2009;44:585–588.
)| false
SantiniVAlmeidaAGiagounidisA. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol2016;34:2988–2996.
SantiniVAlmeidaAGiagounidisA. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol2016;34:2988–2996.
)| false
FenauxPGiagounidisASelleslagD. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood2011;118:3765–3776.
FenauxPGiagounidisASelleslagD. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood2011;118:3765–3776.
)| false
DeegHJJiangPYHolmbergLA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res2004;28:1177–1180.
DeegHJJiangPYHolmbergLA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res2004;28:1177–1180.
)| false
GargRFaderlSGarcia-ManeroG. Phase II study of rabbit antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia2009;23:1297–1302.
GargRFaderlSGarcia-ManeroG. Phase II study of rabbit antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia2009;23:1297–1302.
)| false
PasswegJRGiagounidisAASimcockM. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol2011;29:303–309.
PasswegJRGiagounidisAASimcockM. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol2011;29:303–309.
)| false
DunnDETanawattanacharoenPBoccuniP. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med1999;131:401–408.
DunnDETanawattanacharoenPBoccuniP. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med1999;131:401–408.
)| false
SaunthararajahYNakamuraRNamJM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood2002;100:1570–1574.
SaunthararajahYNakamuraRNamJM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood2002;100:1570–1574.
)| false
SloandEMWuCOGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:2505–2511.
SloandEMWuCOGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:2505–2511.
)| false
StadlerMGermingUKlicheKO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia2004;18:460–465.
StadlerMGermingUKlicheKO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia2004;18:460–465.
)| false
AlsultanAGoldenbergNAKaiserN. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer2009;52:626–630.
AlsultanAGoldenbergNAKaiserN. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer2009;52:626–630.
)| false
MacartneyCFreilichMOdameI. Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. Pediatr Blood Cancer2009;52:525–527.
MacartneyCFreilichMOdameI. Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. Pediatr Blood Cancer2009;52:525–527.
)| false
JerezAClementeMJMakishimaH. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood2013;122:2453–2459.
JerezAClementeMJMakishimaH. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood2013;122:2453–2459.
)| false
GiagounidisAMuftiGJMittelmanM. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol2014;93:429–438.
GiagounidisAMuftiGJMittelmanM. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol2014;93:429–438.
)| false
KuendgenALausekerMListAF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia2013;24:1072–1079.
KuendgenALausekerMListAF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia2013;24:1072–1079.
)| false
RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:86–93.
RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:86–93.
)| false
TomaAKosmiderOChevretS. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia2016;30:897–905.
TomaAKosmiderOChevretS. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia2016;30:897–905.
)| false
EsteyEHThallPFCortesJE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood2001;98:3575–3583.
EsteyEHThallPFCortesJE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood2001;98:3575–3583.
)| false
SonneveldPvan DongenJJHagemeijerA. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia1993;7:963–969.
SonneveldPvan DongenJJHagemeijerA. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia1993;7:963–969.
)| false
AdvaniRSabaHITallmanMS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood1999;93:787–795.
AdvaniRSabaHITallmanMS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood1999;93:787–795.
)| false
WattelESolaryEHecquetB. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Adv Exp Med Biol1999;457:35–46.
WattelESolaryEHecquetB. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Adv Exp Med Biol1999;457:35–46.
)| false
GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:1078–1086.
GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:1078–1086.
)| false
De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151–155.
De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151–155.
)| false
DemuynckHVerhoefGEZacheeP. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant1996;17:745–751.
DemuynckHVerhoefGEZacheeP. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant1996;17:745–751.
)| false
JuradoMDeegHJStorerB. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant2002;8:161–169.
JuradoMDeegHJStorerB. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant2002;8:161–169.
)| false
NevillTJFungHCShepherdJD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood1998;92:1910–1917.
NevillTJFungHCShepherdJD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood1998;92:1910–1917.
)| false
ScottBLSandmaierBMStorerB. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia2006;20:128–135.
ScottBLSandmaierBMStorerB. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia2006;20:128–135.
)| false
WallenHGooleyTADeegHJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol2005;23:3439–3446.
WallenHGooleyTADeegHJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol2005;23:3439–3446.
)| false
RevickiDABrandenburgNAMuusP. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res2013;37:259–265.
RevickiDABrandenburgNAMuusP. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res2013;37:259–265.
)| false
OlivaENLatagliataRLaganaC. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma2013;54:2458–2465.
OlivaENLatagliataRLaganaC. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma2013;54:2458–2465.
)| false
Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:67–71.
Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:67–71.
)| false
NegrinRSSteinRDohertyK. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood1996;87:4076–4081.
NegrinRSSteinRDohertyK. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood1996;87:4076–4081.
)| false
CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321–327.
CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321–327.
)| false
Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344–351.
Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344–351.
)| false
SpiritiMALatagliataRNiscolaP. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol2005;84:167–176.
SpiritiMALatagliataRNiscolaP. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol2005;84:167–176.
)| false
Hellstrom-LindbergEGulbrandsenNLindbergG. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol2003;120:1037–1046.
Hellstrom-LindbergEGulbrandsenNLindbergG. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol2003;120:1037–1046.
)| false
FiliCMalagolaMFolloMY. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res2013;19:3297–3308.
FiliCMalagolaMFolloMY. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res2013;19:3297–3308.
)| false
PlatzbeckerUWongRSVermaA. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol2015;2:e417–426.
PlatzbeckerUWongRSVermaA. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol2015;2:e417–426.
)| false
GiagounidisAMuftiGJFenauxP. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120:1838–1846.
GiagounidisAMuftiGJFenauxP. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer2014;120:1838–1846.
)| false
AlyeaEPKimHTHoV. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood2005;105:1810–1814.
AlyeaEPKimHTHoV. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood2005;105:1810–1814.
)| false
CutlerCSLeeSJGreenbergP. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood2004;104:579–585.
CutlerCSLeeSJGreenbergP. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood2004;104:579–585.
)| false
AlessandrinoEPDella PortaMGBacigalupoA. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood2008;112:895–902.
AlessandrinoEPDella PortaMGBacigalupoA. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood2008;112:895–902.
)| false
LaportGGSandmaierBMStorerBE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant2008;14:246–255.
LaportGGSandmaierBMStorerBE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant2008;14:246–255.
)| false
McCluneBLWeisdorfDJPedersenTL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol2010;28:1878–1887.
McCluneBLWeisdorfDJPedersenTL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol2010;28:1878–1887.
)| false
OlianskyDMAntinJHBennettJM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant2009;15:137–172.
OlianskyDMAntinJHBennettJM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant2009;15:137–172.
)| false
SorrorMLSandmaierBMStorerBE. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA2011;306:1874–1883.
SorrorMLSandmaierBMStorerBE. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA2011;306:1874–1883.
)| false
BokhariSWWatsonLNagraS. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant2012;47:528–534.
BokhariSWWatsonLNagraS. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant2012;47:528–534.
)| false
KorethJPidalaJPerezWS. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol2013;31:2662–2670.
KorethJPidalaJPerezWS. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol2013;31:2662–2670.
)| false
BeranMShenYKantarjianH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer2001;92:1999–2015.
BeranMShenYKantarjianH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer2001;92:1999–2015.
)| false
GoreSDFenauxPSantiniV. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica2013;98:1067–1072.
GoreSDFenauxPSantiniV. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica2013;98:1067–1072.
)| false
SeymourJFFenauxPSilvermanLR. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol2010;76:218–227.
SeymourJFFenauxPSilvermanLR. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol2010;76:218–227.
)| false
KornblithABHerndonJEIISilvermanLR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol2002;20:2441–2452.
KornblithABHerndonJEIISilvermanLR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol2002;20:2441–2452.
)| false
ThomasM. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: GreenbergPL ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263–295.
ThomasM. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: GreenbergPL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263–295.
)| false
